Loading clinical trials...
Loading clinical trials...
A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)
Conditions
Interventions
HCD122
Locations
7
United States
Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102
Boston, Massachusetts, United States
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer
New York, New York, United States
Oregon Health Sciences University
Portland, Oregon, United States
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102
Philadelphia, Pennsylvania, United States
Fred Hutchinson Cancer Research Center Dept. of FHCRC
Seattle, Washington, United States
Novartis Investigative Site
Herston, Queensland, Australia
Start Date
September 1, 2005
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
October 11, 2018
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions